CytoSite will lead initial clinical development with Lantheus having an exclusive option to acquire worldwide development and commercialization rights to the radiotracer. BOSTON, March 26 ...
Investors considering a purchase of Lantheus Holdings Inc (Symbol: LNTH) stock, but tentative about paying the going market price of $102.17/share, might benefit from considering selling puts ...
In trading on Wednesday, shares of Lantheus Holdings Inc (Symbol: LNTH) crossed above their 200 day moving average of $94.93, changing hands as high as $95.94 per share. Lantheus Holdings Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback